+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)
Sale

AI In Oncology Market Outlook 2026-2034: Market Size, Share and Growth Analysis By Component, Treatment Type, Cancer Type, Application

  • PDF Icon

    Report

  • 160 Pages
  • November 2026
  • Region: Global
  • OG Analysis
  • ID: 6272179
UP TO OFF until Jan 01st 2027
The AI In Oncology Market is estimated at USD 2.43 billion in 2026 and is projected to reach USD 19.67 billion by 2034, growing at a CAGR of 29.9% during 2026-2034.

Market Overview

The AI in oncology market covers software, hardware, and services that apply machine learning, deep learning, computer vision, natural-language processing, and multimodal analytics across cancer detection, diagnosis, imaging, pathology, treatment planning, drug discovery, clinical decision support, patient stratification, and research. Solutions are used by hospitals, cancer centers, diagnostic laboratories, pharmaceutical companies, imaging providers, and research organizations, with data inputs spanning radiology, digital pathology, genomics, electronic health records, and real-world evidence. Commercial demand is linked to oncology diagnosis and treatment-planning support. The technical direction includes multimodal analysis and clinically evaluated decision tools, while adoption is constrained by heterogeneous data and incomplete clinical validation. Buyers compare evidence quality, clinical usability and supervised interpretation, making application suitability more important than a broad specification alone. Regional analysis considers North American cancer centers; European oncology networks; Asian diagnostics infrastructure. The report examines these relationships across demand, supply and competitive positioning. It connects customer requirements with implementation barriers and the conditions needed for sustainable commercial participation.

Key Takeaways

  • Demand drivers: Demand is linked to oncology diagnosis and treatment-planning support. Purchasing depends on evidence quality, clinical usability and supervised interpretation, with different users balancing technical value and implementation effort. This makes the relationship between end-use activity and actual supplier orders important to understanding commercial prospects.
  • Technology direction: Multimodal analysis and clinically evaluated decision tools provides a focus for development. Practical adoption still depends on evidence quality, clinical usability and supervised interpretation. Buyers need a clear match between the proposed improvement and their operating requirements, rather than relying on technical novelty as proof of value.
  • Key market distinctions: The supplied segmentation separates By Component; By Treatment Type; By Cancer Type. These divisions should be read as different analytical views rather than added together. Customer requirements and adoption barriers can vary materially between categories, making application-level assessment important when comparing opportunities.
  • Adoption challenges: Heterogeneous data and incomplete clinical validation can limit deployment or lengthen purchasing decisions. Their importance varies with the use case and customer resources. Commercial planning should account for qualification, implementation and support requirements before assuming that demand will translate directly into sustained adoption.
  • Competitive positioning: Tempus AI, Flatiron Health, Paige are among the participants included for comparison. Competitive assessment focuses on evidence quality, clinical usability and supervised interpretation. The relevant distinction is each participant’s role and offering, since suppliers, technology partners and service providers do not necessarily compete across the same activities.
  • Geographic dynamics: The regional picture links North American cancer centers; European oncology networks; Asian diagnostics infrastructure. These settings differ in customer priorities, supply capabilities and purchasing structures. Geographic opportunity therefore depends on local adoption conditions and channel access, without assuming that a single regional pattern describes the entire global market.
  • Buyer economics: Reimbursement, professional training and care-setting capacity influence purchasing. Clinical value must be assessed for the relevant indication or procedure, because broader healthcare spending does not automatically translate into accessible treatment or routine use.
  • Supply and delivery: Quality documentation, controlled handling and reliable availability shape supplier selection. Procurement teams must distinguish the roles of manufacturers, development partners, distributors and care providers when comparing product access with the delivery of services.
  • Routes to market: Specialist referral networks, hospital purchasing and relevant professional channels shape commercial access for AI In Oncology. Requirements involving product authorization, clinical evidence, reimbursement and patient-data or material traceability also affect participation. Suppliers need to understand customer approval processes and channel responsibilities when selecting an expansion strategy or developing a differentiated offering.
  • Strategic opportunities: Collaboration with specialist centers and clearer evidence can strengthen adoption. Opportunities depend on matching the offering to an appropriate clinical or research need, with implementation support that addresses access barriers rather than assuming uniform demand across patient groups.

Market Segmentation

By Component

  • Software Solutions
  • Hardware
  • Services

By Treatment Type

  • Radiotherapy
  • Chemotherapy
  • Immunotherapy
  • Other Treatment Types

By Cancer Type

  • Breast Cancer
  • Lung Cancer
  • Prostate Cancer
  • Colorectal Cancer
  • Brain Tumor
  • Other Cancer Types

By Application

  • Cancer Detection
  • Drug Discovery
  • Drug Development
  • Other Applications

AI In Oncology Market Analytics

The report applies Porter’s Five Forces, value-chain mapping and scenario analysis to the AI In Oncology Market. Supply and demand are examined alongside customer requirements, substitute offerings and adjacent market influences. Analysis of oncology diagnosis and treatment-planning support and multimodal analysis and clinically evaluated decision tools helps explain the conditions supporting adoption. Pricing and procurement dynamics are considered in relation to evidence quality, clinical usability and supervised interpretation. Service delivery, access conditions and the role of implementation partners are considered where relevant. The framework connects product authorization, clinical evidence, reimbursement and patient-data or material traceability with market opportunities and risks, helping readers evaluate operating assumptions and the potential consequences of changing industry conditions.

AI In Oncology Market Competitive Intelligence

The AI In Oncology Market is assessed through participant capabilities, customer relationships and the practical requirements of oncology diagnosis and treatment-planning support. Companies covered include Tempus AI, Flatiron Health, Paige, alongside the complete list below. The comparison considers evidence quality, clinical usability and supervised interpretation, portfolio fit and the ability to respond to heterogeneous data and incomplete clinical validation. Strategic opportunities around multimodal analysis and clinically evaluated decision tools are examined in the context of application needs and delivery capabilities. The analysis distinguishes manufacturers, technology suppliers and service participants where relevant, helping readers assess complementary partnerships as well as direct competition. The profiles help readers distinguish direct competitors from complementary partners and compare strategic fit across the value chain.

Companies Mentioned

  • Tempus AI
  • Flatiron Health
  • Paige
  • PathAI
  • Ibex Medical Analytics
  • Lunit
  • Aidoc
  • Artera
  • ConcertAI
  • Owkin
  • SOPHiA GENETICS
  • Caris Life Sciences
  • Siemens Healthineers
  • GE HealthCare
  • Philips
  • Google Health
  • Oracle Health
  • Medtronic
  • NVIDIA
  • Microsoft

Countries Covered

North America - AI In Oncology Market data and outlook to 2034

  • United States
  • Canada
  • Mexico

Europe - AI In Oncology Market data and outlook to 2034

  • Germany
  • United Kingdom
  • France
  • Italy
  • Spain
  • BeNeLux
  • Russia
  • Sweden

Asia-Pacific - AI In Oncology Market data and outlook to 2034

  • China
  • Japan
  • India
  • South Korea
  • Australia
  • Indonesia
  • Malaysia
  • Vietnam

Middle East and Africa - AI In Oncology Market data and outlook to 2034

  • Saudi Arabia
  • South Africa
  • Iran
  • UAE
  • Egypt

South and Central America - AI In Oncology Market data and outlook to 2034

  • Brazil
  • Argentina
  • Chile
  • Peru
Additional country data and analysis can be included on demand.

Research Methodology

This study combines primary inputs from industry experts across the AI In Oncology value chain with secondary data from associations, government publications, trade databases and company disclosures. Proprietary modeling techniques, including data triangulation, statistical correlation and scenario planning, are applied to support market sizing and forecasting. Market definitions and the roles of different participants are considered when comparing inputs and interpreting the outlook.

Key Questions Addressed

  • What is the current and forecast outlook for the AI In Oncology Market across the covered geographies?
  • How do oncology diagnosis and treatment-planning support influence customer needs and purchasing decisions?
  • What opportunities and barriers are associated with multimodal analysis and clinically evaluated decision tools?
  • How do customers assess evidence quality, clinical usability and supervised interpretation?
  • How are companies responding to heterogeneous data and incomplete clinical validation?
  • Which applications, customer groups and partnership models offer relevant routes to market?
  • How do policy, supply conditions and competitive capabilities affect strategic choices?

Your Key Takeaways from the AI In Oncology Market Report

  • AI In Oncology market size and growth outlook across the covered regions and countries
  • Market-specific trends, demand drivers, adoption challenges and opportunities
  • Assessment of By Component, By Treatment Type, By Cancer Type, By Application
  • Commercial implications of multimodal analysis and clinically evaluated decision tools
  • Competitive positioning and capabilities of the companies mentioned
  • Purchasing considerations involving evidence quality, clinical usability and supervised interpretation
  • Geographic and supply-chain factors associated with North American cancer centers; European oncology networks; Asian diagnostics infrastructure
  • Porter’s Five Forces, value-chain analysis and scenario-based strategic assessment
  • Relevant market developments and their implications for business planning

This product will be delivered within 1-3 business days.

Table of Contents

1. Executive Summary

1.1 AI In Oncology Market scope and key findings1.2 2026 base and 2034 outlook
1.3 Market drivers, constraints and opportunities

2. Market Definition and Methodology

2.1 Product and service boundaries2.2 Geographic coverage: Global
2.3 Valuation basis, units and assumptions
2.4 Data sources and forecast methodology

3. Industry Structure and Market Dynamics

3.1 Value chain and participant roles3.2 Demand drivers and adoption barriers
3.3 Technology and product differentiation
3.4 Pricing and procurement
3.5 Regulation and applicable standards
3.6 Porter’s Five Forces

4. Market Size and Forecast, 2026-2034

4.1 2026 market value (US$ million)4.2 CAGR and annual outlook
4.3 2034 market value (US$ million)
4.4 Forecast assumptions and sensitivity

5. Market Size, Share and Forecast By Component, 2026-2034

5.1 Software Solutions5.2 Hardware
5.3 Services

6. Market Size, Share and Forecast By Treatment Type, 2026-2034

6.1 Radiotherapy6.2 Chemotherapy
6.3 Immunotherapy
6.4 Other Treatment Types

7. Market Size, Share and Forecast By Cancer Type, 2026-2034

7.1 Breast Cancer7.2 Lung Cancer
7.3 Prostate Cancer
7.4 Colorectal Cancer
7.5 Brain Tumor
7.6 Other Cancer Types

8. Market Size, Share and Forecast By Application, 2026-2034

8.1 Cancer Detection8.2 Drug Discovery
8.3 Drug Development
8.4 Other Applications

9. North America Market Outlook

9.1 2026 market size and outlook to 20349.2 Market size and forecast By Component
9.3 Market size and forecast By Treatment Type
9.4 Market size and forecast By Cancer Type
9.5 Market size and forecast By Application
9.6 Country-level trends and demand
9.7 Participant landscape

10. Europe Market Outlook

10.1 2026 market size and outlook to 203410.2 Market size and forecast By Component
10.3 Market size and forecast By Treatment Type
10.4 Market size and forecast By Cancer Type
10.5 Market size and forecast By Application
10.6 Country-level trends and demand
10.7 Participant landscape

11. Asia-Pacific Market Outlook

11.1 2026 market size and outlook to 203411.2 Market size and forecast By Component
11.3 Market size and forecast By Treatment Type
11.4 Market size and forecast By Cancer Type
11.5 Market size and forecast By Application
11.6 Country-level trends and demand
11.7 Participant landscape

12. Middle East and Africa Market Outlook

12.1 2026 market size and outlook to 203412.2 Market size and forecast By Component
12.3 Market size and forecast By Treatment Type
12.4 Market size and forecast By Cancer Type
12.5 Market size and forecast By Application
12.6 Country-level trends and demand
12.7 Participant landscape

13. South and Central America Market Outlook

13.1 2026 market size and outlook to 203413.2 Market size and forecast By Component
13.3 Market size and forecast By Treatment Type
13.4 Market size and forecast By Cancer Type
13.5 Market size and forecast By Application
13.6 Country-level trends and demand
13.7 Participant landscape

14. Company and Ecosystem Analysis

14.1 Product suppliers, developers and enabling participants14.2 Participant portfolios and business models
14.3 Company coverage and role comparison

15. Outlook and Appendix

15.1 Opportunities and constraints15.2 Definitions and abbreviations
15.3 Data limitations and forecast assumptions

Companies Mentioned

  • Tempus AI
  • Flatiron Health
  • Paige
  • PathAI
  • Ibex Medical Analytics
  • Lunit
  • Aidoc
  • Artera
  • ConcertAI
  • Owkin
  • SOPHiA GENETICS
  • Caris Life Sciences
  • Siemens Healthineers
  • GE HealthCare
  • Philips
  • Google Health
  • Oracle Health
  • Medtronic
  • NVIDIA
  • Microsoft

Table Information